3′-Deoxy-3′-fluoro Thymidine

We are 3′-Deoxy-3′-fluoro Thymidine CAS:25526-93-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:3'-Deoxy-3'-fluoro Thymidine
CAS.NO:25526-93-6
Synonyms:3'-Deoxy-3'-fluorothymidine
Molecular Formula:C10H13FN2O4
Molecular Weight:244.22000
 
Physical and Chemical Properties:
Density:1.44
Melting point:176-178ºC
Boiling point:ºC
Flash point:ºC
Index of Refraction:1.565
 
Specification:
Appearance:White to off-white powder
Assay(HPLC):≥98.0%
Loss on drying:≤0.5%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:An antiviral agent.

3'-Deoxy-3'-fluoro Thymidine


Related News: With the improvement of people’s living standards and the aging degree, the demand for medicines has been increasing for a long time. Therefore, the transfer from finished medicines to bulk medicines has greatly promoted the demand for bulk medicines.methyl (2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoate,hydrochloride Featured APIs: Production capacity continues to expand, targeted patents expire. Original research drugs: industry entry barriers are high, performance stability and certainty are high.2,5-Dimethyl-2,5-hexanediol Process: The importance of safety is obvious. The research and development of specialty drug substances (especially high-barrier generic drug substance drugs) usually need to avoid the original process patents, and some chemicals are developed because of the complex structure or the harsh synthetic conditions The synthetic route is more difficult, so the importance of process design capabilities of API companies is becoming more important.3-Hydroxy-3'-nitro-2-naphthanilide CAS:135-65-9 By drawing these distinctions between APIs and the drugs themselves, manufacturers are able to specialize and pharmacists able to align generic equivalents with brand names.Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).

Related Products
Product Name
3-Mercaptopropylmethyldimethoxysilane View Details
Methanesulfonic acid 4,4,5,5,5-pentafluoro-pentyl ester View Details
3-Mercaptopropyltriethoxysilane View Details
ceftaroline fosamil acetate Cas:400827-46-5 manufacturer tris(8-methylnonyl) benzene-1,2,4-tricarboxylate Cas:36631-30-8 manufacturer flusilazole manufacturer 9,10-Dimethoxy-6,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinoline Cas:483-15-8 manufacturer 5-Formylsalicylic acid manufacturer